Search Results - "sodium/glucose cotransporter 2"

Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options by Cornell S

Connect to this object online.

A practical review of diabetes mellitus type 2 treatment in primary care by Call Justin T., Cortés Pedro, Harris Dana M.

Connect to this object online.

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date by Cinti F, Moffa S, Impronta F, Cefalo CMA, Sun VA, Sorice GP, Mezza T, Giaccari A

Connect to this object online.

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond by Elif A Oral

Connect to this object online.

Effects of Empagliflozin on Gut Microbiota in Heart Failure with a Preserved Ejection Fraction: The Design of a Pragmatic Randomized, Open-Label Controlled Trial (EMPAGUM) by Guan XQ, Wang CH, Cheng P, Fu LY, Wu QJ, Cheng G, Guan L, Sun ZJ

Connect to this object online.

Skin-Related Adverse Reactions Induced by Oral Antidiabetic Drugs-A Review of Literature and Case Reports by Justyna Kowalska, Dorota Wrześniok

Connect to this object online.

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland by Hallinen T, Kivelä S, Soini E, Harjola VP, Pesonen M

Connect to this object online.

Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects by Xiao Li, Yue Yao, Luoyifan Zhou, Jin Yang, Xin Chen, Chao Zhang, Manjiong Wang, Jian Li, Baoli Li, Yixiang Xu

Connect to this object online.

NLRP3 Inflammasome - a new universal target of asymptomatic hyperuricemia and gout management by P. A. Lebedev, L. T. Volova, N. K. Osina, E. V. Paranina

Connect to this object online.

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin by Andrew Ahmann

Connect to this object online.

Ertugliflozin in the treatment of type 2 diabetes mellitus by Joel C Marrs, Sarah L Anderson

Connect to this object online.

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction by Oscar Eduardo Ospina González, Diana Catalina Llanos Mejía, Edgardo Kaplinsky, Alejandro Barbagelata, Sergio Perrone

Connect to this object online.

Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice by Panshuang Qiao, Yingli Jia, Yingli Jia, Ang Ma, Jinzhao He, Chen Shao, Xiaowei Li, Shuyuan Wang, Baoxue Yang, Hong Zhou

Connect to this object online.

Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers by Chen Q, Yu C, Wu Q, Song R, Liu Y, Feng S, Yu C, Jia J

Connect to this object online.

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function by Daniel H. Van Raalte, Hiddo Lambers Heerspink

Connect to this object online.

Pharmacokinetics and Tissue Distribution of Enavogliflozin in Mice and Rats by Minyeong Pang, So Yeon Jeon, Min-Koo Choi, Ji-Hyeon Jeon, Hye-Young Ji, Ji-Soo Choi, Im-Sook Song

Connect to this object online.

SGLT2 inhibitors - a breakthrough in treatment of heart failure and their multipotential beneficial role in cardiology, diabetology, nephrology and neurology by Marta Bogowska, Aleksandra Berner, Klaudia Marczyk, Karolina Matyja, Anna Olszewska, Maciej Pękała, Paulina Polak, Monika Polaszek, Karina Stelmaszak, Katarzyna Stencel

Connect to this object online.

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure by Edgardo Kaplinsky

Connect to this object online.

CX3CL1 Worsens Cardiorenal Dysfunction and Serves as a Therapeutic Target of Canagliflozin for Cardiorenal Syndrome by Cankun Zheng, Wanling Xuan, Zhenhuan Chen, Zhenhuan Chen, Rui Zhang, Xiaoxia Huang, Yingqi Zhu, Siyuan Ma, Kaitong Chen, Lu Chen, Mingyuan He, Hairuo Lin, Wangjun Liao, Jianping Bin, Jianping Bin, Yulin Liao, Yulin Liao

Connect to this object online.

Editorial: Diabetic kidney disease: routes to drug development, pharmacology and underlying molecular mechanisms by Divya Bhatia, Divya Bhatia, Swayam Prakash Srivastava

Connect to this object online.